Latest Mergers And Acquisitions News

Experience Co Limited reported a 5% increase in sales revenue to $67.2 million for 1H26, with underlying EBITDA steady at $10.5 million despite operational challenges. The company is streamlining its portfolio by selling Wild Bush Luxury and focusing on scalable adventure experiences.

Mayfield Group Holdings has announced the acquisition of SMEC Power & Technology for up to $30 million, marking its entry into underground mining electrical infrastructure and international markets.

FortifAI Limited reported a 51% revenue decline but a 70% reduction in net loss for H1 FY26, alongside completing a major AI technology acquisition and securing $5 million in fresh capital.

First Graphene Limited reported a strong 53% revenue increase driven by new industrial applications, yet posted a $3.35 million net loss influenced by non-cash finance costs. The company’s recent $3.5 million capital raise positions it to focus on commercial expansion without further funding.

betr Entertainment has extended its NAB facility agreement maturity to July 2027, reinforcing its financial flexibility and growth ambitions. This move underscores a strong partnership with NAB amid betr’s evolving wagering business.

State Street SPDR Core Equity ETFs have reported consistent half-year results for the period ending 31 December 2025, maintaining alignment with their benchmark indices and continuing to provide reliable distributions to unitholders.

Cyclopharm Limited reported a 17% revenue increase to a record $32.3 million in 2025, powered by a 226% surge in US Technegas sales. The company is accelerating its US rollout with plans for up to 300 installations in 2026, while advancing clinical trials beyond pulmonary embolism.

TPC Consolidated Limited reported a 4.1% revenue increase to $103.6 million and a 62% jump in underlying EBITDA for the half-year ended December 2025, while the proposed acquisition scheme faces regulatory hurdles.

Cleo Diagnostics reported a 53% drop in revenues and a slight increase in net loss to $1.98 million for H1 2025, while progressing its pivotal FDA clinical trial for an ovarian cancer blood test with strong regulatory and commercial milestones.

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.

DUG Technology’s US subsidiary has been ordered to pay over US$2 million following a breach of contract ruling, but the company is gearing up to contest the judgment through appeals.

Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.